Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
New HIV/AIDS study results reported from M.J. Mcelrath et al
January 7th, 2009
" In the Step Study, the MRKAd5 HIV-1 gag/pol/nef vaccine did not reduce plasma viraemia after infection, and HIV-1 incidence was higher in vaccine-treated than in placebo-treated men with pre-existing adenovirus serotype 5 (ALIS) immunity. We assessed vaccine-induced immunity and its potential contributions to infection risk," researchers in the United States report. " To assess immunogenicity, we characterised HIV-specific T cells ex vivo with validated interferon-Y ELISPOT and intracelluilar cytokine staining assays, using a case-cohort design. To establish effects of vaccine and pre-existing Ad5 immunity on infection risk, we undertook flow cytometric studies to...
Source: Vaccine Weekly (2009-01-07)
|
